Prothena | PRTA - Net Income


Prothena reported $32.72M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Exelixis USD 210.47M 34.06M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Prothena USD 32.72M 54.31M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026